Sugi Predict

Sugi Predict / Compounds / SCHEMBL8628188

SCHEMBL8628188

SCHEMBL8628188

CCCC[C@H](NC=O)C(=O)O

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ ADH1B P00325 1/20 0.46
▸ ADH1C P00326 1/20 0.46
▸ ADH1A P07327 1/20 0.46
▸ ADH4 P08319 1/20 0.46
▸ ADH7 P40394 1/20 0.46
▸ CA2 P00918 2/20 0.45
▸ MAPK1 P28482 1/20 0.45
▸ NOD1 Q9Y239 5/20 0.45
▸ MAPT P10636 1/20 0.42
▸ HDAC2 Q92769 1/20 0.42
▸ SLC15A1 P46059 1/20 0.42
▸ ACHE P22303 1/20 0.41
▸ BACE1 P56817 1/20 0.41
▸ GPR84 Q9NQS5 3/20 0.39
▸ FFAR1 O14842 1/20 0.39
▸ SLC6A5 Q9Y345 1/20 0.39
▸ SLC1A3 P43003 1/20 0.39
▸ SLC1A2 P43004 1/20 0.39
▸ SLC1A1 P43005 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8628191 1.00 ADH1B (0.46) ADH1BADH1CADH1AADH4ADH7
SCHEMBL28318789 0.92 ADH1B (0.56) ADH1BADH1CADH1AADH4ADH7
SCHEMBL20366018 0.92 ADH1B (0.56) ADH1BADH1CADH1AADH4ADH7
SCHEMBL17706682 0.88 CHRM1 (0.44) ADH1BADH1CADH1AADH4ADH7
SCHEMBL14819043 0.88 CHRM1 (0.44) ADH1BADH1CADH1AADH4ADH7
Leucine SCHEMBL6461855 0.84 SLC7A5 (0.51) NOD1SLC15A1SLC1A3SLC1A2SLC1A1
SCHEMBL20806152 0.83 DPP7 (0.42) ADH1BADH1CADH1AADH4ADH7
SCHEMBL4955832 0.83 HDAC2 (0.40) ADH1BADH1CADH1AADH4ADH7
SCHEMBL13351177 0.81 MME (0.45) ADH1BADH1CADH1AADH4ADH7
SCHEMBL13350786 0.81 SLC15A1 (0.43) ADH1BADH1CADH1AADH4ADH7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2813512-B1 PEPTIDE-COMPOUND CYCLIZATION METHOD CHUGAI PHARMACEUTICAL CO LTD (JP) 2021-03-31 — — EP claimed
US-9409952-B2 Peptide-compound cyclization method CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2016-08-09 — — US claimed
US-20150080549-A1 PEPTIDE-COMPOUND CYCLIZATION METHOD CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2015-03-19 — — US claimed
EP-2813512-A1 PEPTIDE-COMPOUND CYCLIZATION METHOD Chugai Seiyaku Kabushiki Kaisha (JP) 2014-12-17 — — EP claimed
US-12415835-B2 Peptide-compound cyclization method CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2025-09-16 — — US disclosed
US-20240173375-A1 CHEMOTACTIC AUTOPHAGY-INHIBITING PEPTIDE, COMPOSITIONS AND METHODS RELATED THERETO BIOTEMPT B.V. (NL) 2024-05-30 — — US disclosed
US-20240166689-A1 PEPTIDE-COMPOUND CYCLIZATION METHOD CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2024-05-23 — — US disclosed
US-11891457-B2 Peptide-compound cyclization method CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2024-02-06 — — US disclosed
EP-3974563-A1 CYCLIC PEPTIDES Chugai Seiyaku Kabushiki Kaisha (JP) 2022-03-30 — — EP disclosed
EP-2813512-B1 PEPTIDE-COMPOUND CYCLIZATION METHOD CHUGAI PHARMACEUTICAL CO LTD (JP) 2021-03-31 — — EP disclosed
US-20210061860-A1 PEPTIDE-COMPOUND CYCLIZATION METHOD CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2021-03-04 — — US disclosed
US-20200131669-A1 CYCLIC PEPTIDE COMPOUND HAVING HIGH MEMBRANE PERMEABILITY, AND LIBRARY CONTAINING SAME CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2020-04-30 — — US disclosed
US-9409952-B2 Peptide-compound cyclization method CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2016-08-09 — — US disclosed
US-20150080549-A1 PEPTIDE-COMPOUND CYCLIZATION METHOD CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) 2015-03-19 — — US disclosed
EP-2813512-A1 PEPTIDE-COMPOUND CYCLIZATION METHOD Chugai Seiyaku Kabushiki Kaisha (JP) 2014-12-17 — — EP disclosed
US-5811394-A CAN BE TARGETED TO SPECIFIC SITES DIATIDE, INC. (US) 1998-09-22 — — US disclosed
US-5788960-A RADIOLOGY; DIAGNOSTIC AGENTS DIATECH, INC. (US) 1998-08-04 — — US disclosed
US-5681541-A (OLIGO OR POLY)PEPTIDES DIATIDE, INC. (US) 1997-10-28 — — US disclosed
US-5654272-A INCLUDING AN AMINO ACID SEQUENCE OF CYSTEINE-(AMINO ACID)-CYSTEINE TO COMPLEX THE ISOTOPE AND A TARGET BINDING SEQUENCEFOR TARGET SITES INCLUDING ATHEROSCLEROTIC PLAQUE AND ALZHEIMER'S AMYLOID PLAQUE; SCINTIGRAPHY DIATIDE, INC. (US) 1997-08-05 — — US disclosed
US-5451663-A Fluorescent dyes MOLECULAR PROBES, INC. (US) 1995-09-19 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11891457-B2 Peptide-compound cyclization method VIP, NGLY1, GLP1R ADH1B 4832/4885ADH1C 4793/4885ADH1A 4885/4885
US-20210061860-A1 PEPTIDE-COMPOUND CYCLIZATION METHOD VIP, NGLY1, GLP1R ADH1B 4832/4885ADH1C 4793/4885ADH1A 4885/4885
US-20240166689-A1 PEPTIDE-COMPOUND CYCLIZATION METHOD VIP, NGLY1, GLP1R ADH1B 4832/4885ADH1C 4793/4885ADH1A 4885/4885
US-20200131669-A1 CYCLIC PEPTIDE COMPOUND HAVING HIGH MEMBRANE PERMEABILITY, AND LIBRARY CONTAINING SAME VIP, SLC7A1, TRPV1 ADH1B 4655/4885ADH1C 4537/4885ADH1A 4592/4885
US-20150080549-A1 PEPTIDE-COMPOUND CYCLIZATION METHOD VIP, NGLY1, GLP1R ADH1B 4832/4885ADH1C 4793/4885ADH1A 4885/4885
US-12415835-B2 Peptide-compound cyclization method VIP, NGLY1, GLP1R ADH1B 4832/4885ADH1C 4793/4885ADH1A 4885/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.